MarketPeel
Insider Trading Intelligence
FS

Frank M. Sands

ABOS
10% OWNER · ACUMEN PHARMACEUTICALS, INC. · CIK 0001870494
FILING MIX · LIFETIME67%/33%
BUYS
4
SELLS
2
TOTAL VALUE
$9.70M
COMPANIES
2
ACTIVE SINCE
Jul 2021
HOLDINGS NOW
14,143,694
AVG SELL PX
TRADE KIND
SHOWING 6 / 6
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Frank M. Sands, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%-2.11%+2.16%-4.27%-4.27%
14d2+50.00%-3.85%+1.81%-5.65%-5.65%
30d2+50.00%-7.19%+2.98%-10.17%-10.17%
60d2+50.00%-6.04%+3.73%-9.78%-9.78%
90d2+50.00%-4.11%+1.59%-5.71%-5.71%
180d2+50.00%-30.66%+11.86%-42.52%-42.52%
1y2(1 pending)+0.00%-72.77%-10.21%-62.56%-62.56%
2y2(1 pending)+0.00%-75.00%+4.69%-79.69%-79.69%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABOS · 1,124,729 shares · as of Jul 6, 2021
0854,2691,708,5382,562,8063,417,075SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
FLOW · 4 buys / 2 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IKT
INHIBIKASE THERAPEUTICS, INC.
PURCHASE
2,068,965$1.45$3.00M13,018,965Nov 21, 2025Nov 24, 2025View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
1,842,3460Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
1,124,7290Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
450,000$14.88$6.70M3,417,075Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
1,842,3462,967,075Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
1,124,7291,124,729Jul 6, 2021Jul 8, 2021View →
Other insiders · ABOS
Loading peer insiders…
About this filer
CIK 0001870494
ROLE
10% Owner
PRIMARY
ABOS
COMPANIES
2
ACTIVE SINCE
Jul 2021
MARKETPEEL · /INSIDER/0001870494DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback